Abstract:Abstract Glial cells, including astrocytes and oligodendrocytes are important for normal brain function. In many neurodegenerative diseases glial cells undergo significant morphological, functional and gene expression changes termed reactive gliosis. The cause, identity and neuroprotective or neurotoxic nature of these changes remains incompletely understood. This knowledge in needed to develop a framework of how individual pathological changes in glial cells contribute to progressive dysfunction and selective neuronal vulnerability in neurodegenerative diseases. This is particularly relevant during the early disease stages that allow for the effective therapies and reversal or slowing of disease phenotypes. Spinocerebellar ataxia type 1 (SCA1) is a progressive neurodegenerative disease caused by an abnormal expansion of CAG repeats in the gene Ataxin1 ( ATXN1 ). While mutant ATXN1 is expressed broadly throughout the brain, SCA1 is characterized by severe degeneration of cerebellar Purkinje cells (PCs). Despite major advances in dissecting the effects of mutant ATXN1 on Purkinje cells, much less is understood how cerebellar astrocytes and oligodendrocytes respond to and contribute to Purkinje cell dysfunction in SCA1. To address this question we performed cerebellar single nuclei RNA sequencing (snRNA seq) of early disease stage Pcp2-ATXN1[82Q] mice, a transgenic SCA1 mouse model expressing mutant ATXN1 only in Purkinje cells. We found no changes in cell numbers in the SCA1 cerebellum. We validated previously indicated pathway and gene expression changes in the Purkinje cells, and identified novel DEG and pathways in Purkinje cells, including Ralyl that may provide compensatory roles and maintain PC function. Importantly we identified profound non-cell autonomous and potentially neuroprotective gene expression and pathway alterations in Bergman glia, velate astrocytes and oligodendrocytes that may contribute to disease pathogenesis.

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Piperine Ameliorates SCA17 Neuropathology by Reducing ER Stress

Polyglutamine spinocerebellar ataxias — from genes to potential treatments

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion

Polyglutamine spinocerebellar ataxias: emerging therapeutic targets

Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models

Spinal cord phosphoproteome of a SCA2/ALS13 mouse model reveals alteration of ATXN2-N-term SH3-actin interactome and of autophagy via WNK1-MYO6-OPTN-SQSTM1

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

Investigating the therapeutic effects of novel compounds targeting inflammatory IL-1β and IL-6 signaling pathways in spinocerebellar ataxia type 3

Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7

Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies

Functional implications of paralog genes in polyglutamine spinocerebellar ataxias

Polyglutamine-Expanded Ataxin-7 Antagonizes CRX Function and Induces Cone-Rod Dystrophy in a Mouse Model of SCA7

Single-nuclei RNA sequencing uncovers non-cell autonomous changes in cerebellar astrocytes and oligodendrocytes that may contribute to Spinocerebellar Ataxia Type 1 (SCA1) pathogenesis

Single nuclei RNA sequencing investigation of the Purkinje cell and glial changes in the cerebellum of transgenic Spinocerebellar ataxia type 1 mice

Small Molecules Inducing Autophagic Degradation of Expanded Polyglutamine Protein through Interaction with Both Mutant ATXN3 and LC3

An insight into advances in the pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3

The BAG2 and BAG5 Proteins Inhibit the Ubiquitination of Pathogenic Ataxin3-80Q.

Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3

A Drosophila Model of the Neurodegenerative Disease SCA17 Reveals a Role of RBP-J/Su(H) in Modulating the Pathological Outcome.

Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways